Ayşe Yürekli1, Atakan Ölçenoğlu1, Manolya Yıldız1, Begüm Arda1, Oytun Erbaş2

1Institute of Experimental Medicine, Gebze-Kocaeli, Turkey
2Department of Physiology, Medical Faculty of Demiroğlu Bilim University, Istanbul, Turkey

Keywords: Benign prostatic hyperplasia, neurodegenerative diseases, neuroprotection, terazosin.


Terazosin (TZ) is a medication approved by the Food and Drug Administration (FDA) for use in the treatment of hypertension, as it lowers blood pressure. However, it was eventually discovered to be beneficial in the treatment of benign prostatic hyperplasia, and it was used to treat this disease as well. In addition to these two fields, the effects of TZ on neurodegenerative disorders are still unknown. Neurodegenerative disorders are caused by the loss of neurons. Their loss can also lead to the formation of diseases such as Parkinson's disease (PD), Alzheimer's disease, and Huntington's disease. The body uses the neuroprotection system to prevent certain disorders. In neurodegenerative disorders, it is thought that the combination and precise use of TZ and neuroprotection may have positive outcomes. The effects of TZ on PD are currently being studied.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.